Current and emerging pharmacotherapies for treating tobacco dependence
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Tobacco dependence remains the leading cause of death and disease in the US and a major cause of mortality around the world, yet 1 out of 5 American adults smoke and 1.3 billion adults smoke worldwide. Nicotine replacement therapies (NRTs), bupropion and varenicline, are approved by the US FDA as first-line treatments for nicotine dependence. Clonidine and nortriptyline are recommended as second-line treatments by the Agency for Healthcare Research and Quality. Although recent data suggest that varenicline is superior to bupropion for treating nicotine dependence, a majority of smokers fail to maintain long-term abstinence from smoking using FDA-approved pharmacotherapies. Thus, continued investigation of novel medications for nicotine dependence remains a critical priority. Guided by research on multiple neurobiological mechanisms of nicotine dependence, several novel medications that mimic and/or attenuate nicotine's rewarding effects, or reduce nicotine withdrawal, are under investigation. Although existing data are limited or conflicting, there is some evidence for the efficacy of selegiline, fluoxetine, naltrexone and mecamylamine in certain subgroups of smokers. New research directions, such as fast-acting NRTs, the tailored use of NRTs for subtypes of smokers, and pharmacogenetics, hold promise for new treatment approaches and, ultimately, for reducing rates of tobacco use in the US and worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Is there a common molecular pathway for addiction?
Nestler, E. J. (2005) · Nature Neuroscience · doi:10.1038/nn1578 · Cited by 1,388 · cited 1×
“Nicotine stimulates increased burst firing of dopamine neurons via α4β2-nAChRs and also stimulates dopamine release indirectly by activating excitatory glutamate neurons via α7-nAChRs [82,83].”
BackgroundGonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 2×
“The first two trials randomised 2052 smokers to placebo, bupropion 300 mg, or varenicline 2 mg for 12 weeks and assessed quit rates up to 1 year following the start of treatment [12,61].”
BackgroundNicotine replacement therapy for smoking cessation
Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub2 · Cited by 972
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930 · cited 2×
“By activating α4β2-nAChRs, which are expressed widely on dopamine and GABA neurons in the ventral tegmental area, varenicline attenuates nicotine’s effect on dopamine release, while maintaining dopaminergic tone [60].”
BackgroundTonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660 · cited 1×
“In a third study [62], smokers received open-label varenicline”
BackgroundBupropion is a nicotinic antagonist
Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38905-0 · Cited by 509
Nicotine addiction and comorbidity with alcohol abuse and mental illness
Dani, J. A., & Harris, R. A. (2005) · Nature Neuroscience · doi:10.1038/nn1580 · Cited by 382 · cited 1×
“Nicotine stimulates increased burst firing of dopamine neurons via α4β2-nAChRs and also stimulates dopamine release indirectly by activating excitatory glutamate neurons via α7-nAChRs [82,83].”
BackgroundNeurobiology of the nicotine withdrawal syndrome
Kenny, P. J., & Markou, A. (2001) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00651-7 · Cited by 310 · cited 1×
“Effects of chronic nicotine on these neurobiological pathways contribute further to somatic, cognitive and affective symptoms of nicotine withdrawal [91].”
BackgroundMaurer, P., Jennings, G. T., Willers, J., Rohner, F., Lindman, Y., Roubicek, K., Renner, W. A., Müller, P., & Bachmann, M. F. (2005) · European Journal of Immunology · doi:10.1002/eji.200526285 · Cited by 279 · cited 2×
“This approach is designed to use nicotine-specific antibodies to prevent nicotine from crossing the blood–brain barrier and to decrease the rate of nicotine metabolism [126,127].”
BackgroundMethod
Cited by
Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21st Century
Laniado-Laborín, R. (2009) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph6010209 · Cited by 361
Varenicline improves mood and cognition during smoking abstinence
Patterson, F., Jepson, C., Strasser, A. A., Loughead, J., Perkins, K. A., Gur, R. C., Frey, J. M., Siegel, S., & Lerman, C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.028 · Cited by 222
Self-citationNicotine exposure during adolescence induces a depression-like state in adulthood
Iñiguez, S. D., Warren, B. L., Parise, E. M., Alcantara, L. F., Schuh, B., Maffeo, M. L., Manojlovic, Z., & Bolaños-Guzmán, C. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.220 · Cited by 157
“These observations are in agreement with basic and clinical studies showing that nicotine has antidepressant properties (Salin-Pascual et al, 1996; Suemaru et al, 2006; Tizabi et al, 1999; VazquezPalacios et al, 2004), the well-known effects of antidepressant treatment in the FST (Cryan et al, 2002), and with studies…”
Weerts, E. M., Kim, Y. K., Wand, G. S., Dannals, R. F., Lee, J. S., Frost, J. J., & McCaul, M. E. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301440 · Cited by 147
Conti, D. V., Lee, W., Li, D., Liu, J., Van Den Berg, D., Thomas, P. D., Bergen, A. W., Swan, G. E., Tyndale, R. F., Benowitz, N. L., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn181 · Cited by 136
Self-citation
Metadata
- Authors
- Schnoll, R. A., & Lerman, C.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa Healthcare
- Published
- 2006-08-29
- Volume
- 11
- Issue
- 3
- Pages
- 429-444
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2105769355
- Cited by
- 119
- References
- 22
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current and emerging pharmacotherapies for treating tobacco dependence. https://app.cochat.ai/papers/10.1517/14728214.11.3.429
- The paper
- Schnoll, R. A., & Lerman, C. (2006). Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opinion on Emerging Drugs. https://doi.org/10.1517/14728214.11.3.429
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.